Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT03178552
PHASE2/PHASE3

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

Sponsor: Hoffmann-La Roche

View on ClinicalTrials.gov

Summary

This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by a blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assay.

Official title: A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

1000

Start Date

2017-09-22

Completion Date

2026-10-31

Last Updated

2026-03-09

Healthy Volunteers

No

Interventions

DRUG

Alectinib

Participants will receive 600 mg BID (Cohort A); 900, 1200, or 750 mg BID (Cohort B) or RP2D BID; orally until disease progression, unacceptable toxicity, withdrawal of consent or death.

DRUG

Atezolizumab

Participants will receive atezolizumab 1200 mg IV infusion Q21D (Cohorts C and F) or 1680 mg IV infusion Q4W starting on Day 29 (Cohort E).

DRUG

Pemetrexed

Participants will receive pemetrexed 500 mg/m\^2 IV infusion on Day 1 Q21D.

DRUG

Cisplatin

Participants will receive cisplatin 75 mg/m\^2 IV on Day 1 Q21D.

DRUG

Carboplatin

Participants will receive carboplatin of AUC 5 or 6 IV on Day 1 Q21D.

DRUG

Gemcitabine

Participants will receive gemcitabine 1000 or 1250 mg/m\^2 on Days 1 and 8 of every cycle (1 Cycle=21 days).

DRUG

Entrectinib

Participants will receive entrectinib 600 mg orally QD.

DRUG

Cobimetinib

Participants will receive 60 mg PO QD on Days 1-21 of the initial run-in and triple-combination periods.

DRUG

Vemurafenib

Participants will receive 960 mg PO BID on Days 1-21 of the initial run-in period, and 720 mg PO BID on Days 22-28 of the initial run-in period and on Days 1-28 of each cycle during the triple-combination period.

DRUG

Bevacizumab

Participants will receive 15 mg/kg of IV bevacizumab on Day 1 of each 21-day cycle during the induction and maintenance periods.

DRUG

Divarasib

Participants will receive divarasib PO QD until disease progression or unacceptable toxicity.

DRUG

Docetaxel

Participants will receive IV docetaxel Q3W (75 mg/m\^2) until disease progression or unacceptable toxicity

Locations (164)

UC Davis

Sacramento, California, United States

Rocky Mountain Cancer Center

Denver, Colorado, United States

SCRI Florida Cancer Specialists South

Fort Myers, Florida, United States

Florida Cancer Specialist, North Region

St. Petersburg, Florida, United States

University of Kentucky

Lexington, Kentucky, United States

Comprehensive Cancer Centers of Nevada

Las Vegas, Nevada, United States

Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire, United States

Weill Cornell Medical College-New York Presbyterian Hospital

New York, New York, United States

Montefiore Medical Center

The Bronx, New York, United States

Oregon HSU

Portland, Oregon, United States

St. Luke's University Health network

Bethlehem, Pennsylvania, United States

Sarah Cannon Research Institute / Tennessee Oncology

Chattanooga, Tennessee, United States

Fundación CENIT para la Investigación en Neurociencias

Buenos Aires, Argentina

Hospital Italiano

Buenos Aires, Argentina

Hospital Britanico de Buenos Aires

Ciudad Autonoma Buenos Aires, Argentina

Royal North Shore Hospital

St Leonards, New South Wales, Australia

The Prince Charles Hospital

Chermside, Queensland, Australia

Ashford Cancer Center Research

Kurralta Park, South Australia, Australia

UZ Brussel

Brussels, Belgium

Cliniques Universitaires St-Luc

Brussels, Belgium

UZ Leuven Gasthuisberg

Leuven, Belgium

Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda

Ijuí, Rio Grande do Sul, Brazil

Hospital Sao Lucas - PUCRS

Porto Alegre, Rio Grande do Sul, Brazil

Instituto do Cancer do Estado de Sao Paulo - ICESP

São Paulo, São Paulo, Brazil

Instituto Nacional de Cancer - INCa

Rio de Janeiro, Brazil

Cross Cancer Institute

Edmonton, Alberta, Canada

CancerCare Manitoba

Winnipeg, Manitoba, Canada

Royal Victoria Regional Health Centre

Barrie, Ontario, Canada

William Osler Health System Brampton Civic Hospital

Brampton, Ontario, Canada

London Health Sciences Centre · Victoria Hospital

London, Ontario, Canada

Lakeridge Health Center

Oshawa, Ontario, Canada

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

Princess Margaret Cancer Center

Toronto, Ontario, Canada

Jewish General Hospital

Montreal, Quebec, Canada

IUCPQ (Hôpital Laval)

Québec, Quebec, Canada

Saskatoon Cancer Centre

Saskatoon, Saskatchewan, Canada

Bradford Hill Centro de Investigaciones Clinicas

Recoleta, Chile

Beijing Cancer Hospital

Beijing, China

Jilin Cancer Hospital

Changchun, China

Hunan Cancer Hospital

Changsha, China

The second Xiangya hospital of central south university

Changsha, China

Sichuan Cancer Hospital

Chengdu, China

West China Hospital - Sichuan University

Chengdu, China

The First Affiliated Hospital of Guangzhou Medical University Pharmacy

Guangzhou, China

Zhejiang Cancer Hospital

Hangzhou, China

Shandong Cancer Hospital

Jinan, China

The Second Affiliated Hospital to Nanchang University

Nanchang, China

Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School

Nanjing, China

Fudan Unviversity Shanghai Cancer Center

Shanghai, China

First Affiliated Hospital of Medical College of Xi'an Jiaotong University

Xi'an, China

Institut Bergonie CLCC Bordeaux

Bordeaux, France

Centre Francois Baclesse

Caen, France

Centre Oscar Lambret

Lille, France

Centre Léon Bérard

Lyon, France

Hopital Caremeau

Nîmes, France

Hopital Robert Schuman

Nouilly, France

Hôpital Européen Georges Pompidou

Paris, France

Hopital Tenon

Paris, France

CHU Poitiers

Poitiers, France

Hopital Pontchaillou

Rennes, France

CHU de Toulouse - Hôpital Larrey

Toulouse, France

Klinikum Chemnitz gGmbH

Chemnitz, Germany

Asklepios-Fachklinik Muenchen-Gauting

Gauting, Germany

Thoraxklinik Heidelberg gGmbH

Heidelberg, Germany

HSK Dr.-Horst-Schmidt-Kliniken Klinik für Innere Medizin III Onkologie Hämatologie und Palliativmed

Wiesbaden, Germany

Queen Mary Hospital

Hong Kong, Hong Kong

Prince of Wales Hosp

Shatin, Hong Kong

Soroka Medical Center

Beersheba, Israel

Rambam Health Care Campus

Haifa, Israel

Meir Medical Center

Kfar Saba, Israel

Rabin MC

Petah Tikva, Israel

Chaim Sheba Medical Center

Ramat Gan, Israel

Sourasky / Ichilov Hospital; Dept. of Oncology

Tel Aviv, Israel

Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale

Naples, Campania, Italy

IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola

Meldola, Emilia-Romagna, Italy

Irccs Centro Di Riferimento Oncologico (CRO)

Aviano, Friuli Venezia Giulia, Italy

Azienda Ospedaliera San Camillo Forlanini

Rome, Lazio, Italy

Asst Papa Giovanni XXIII

Bergamo, Lombardy, Italy

ASST di Cremona - Azienda Socio Sanitaria Territoriale di Cremona

Cremona, Lombardy, Italy

Irccs Istituto Europeo di Oncologia (IEO)

Milan, Lombardy, Italy

Asst Di Monza

Monza, Lombardy, Italy

Azienda Sanitaria Ospedaliera S Luigi Gonzaga

Orbassano (TO), Piedmont, Italy

Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital

Bunkyō City, Japan

National Hospital Organization Kyushu Medical Center

Fukuoka, Japan

National Hospital Organization Kyushu Cancer Center

Fukuoka, Japan

Kyushu University Hospital

Fukuoka, Japan

Hiroshima University Hospital

Hiroshima, Japan

Kanazawa University Hospital

Ishikawa, Japan

Kanagawa Cancer Center

Kanagawa, Japan

University Hospital Kyoto Prefectural University of Medicine

Kyoto, Japan

Shikoku Cancer Center

Matsuyama, Japan

Tohoku University Hospital

Miyagi, Japan

Sendai Kousei Hospital

Miyagi, Japan

Niigata University Medical & Dental Hospital

Niigata, Japan

Niigata Cancer Center Hospital

Niigata, Japan

Kindai University Hospital

Osaka, Japan

Saga University Hospital

Saga, Japan

Shizuoka Cancer Center

Shizuoka, Japan

Juntendo University Hospital

Tokyo, Japan

The Cancer Institute Hospital of JFCR

Tokyo, Japan

Kyorin University Hospital

Tokyo, Japan

Fujita Health University Hospital

Toyoake-shi, Japan

Wakayama Medical University Hospital

Wakayama, Japan

National Hospital Organization Yamaguchi - Ube Medical Center

Yamaguchi, Japan

Hospital Angeles Tijuana

Tijuana, Estado de Baja California, Mexico

Health Pharma Professional Research

Mexico City, Mexico CITY (federal District), Mexico

AVIX Investigación Clínica S.C

Monterrey, Nuevo León, Mexico

Oncologico Potosino

San Luis Potosí City, San Luis Potosí, Mexico

Auckland City Hospital

Auckland, New Zealand

Hemato Oncología de Panamá Especializada

Panama City, Panama

Hospital Nacional Edgardo Rebagliati Martins

Lima, Peru

Instituto Nacional de Enfermedades Neoplasicas

Lima, Peru

Instituto Peruano de Oncología y Radioterapia

Lima, Peru

Clinica Ricardo Palma

San Isidro, Peru

Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii

Gda?sk, Poland

Krakowski Szpital Specjalistyczny im sw.Jana Pawla II

Krakow, Poland

Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie

Olsztyn, Poland

Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy

Otwock, Poland

Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu

Poznan, Poland

Centrum Onkologii Instytut im.Marii Sklodowskiej-Curie

Warsaw, Poland

Moscow City Oncology Hospital #62

Moscovskaya Oblast, Moscow Oblast, Russia

Principal Military Clinical Hospital n.a. N.N. Burdenko

Moscow, Moscow Oblast, Russia

S-Pb clinical scientific practical center of specialized kinds of medical care (oncological)

Saint Petersburg, Sankt-Peterburg, Russia

Clinical Oncology Dispensary

Omsk, Russia

Clinical Center of Serbia

Belgrade, Serbia

University Hospital Medical Center Bezanijska kosa

Belgrade, Serbia

Institute for Pulmonary Diseases of Vojvodina

Kamenitz, Serbia

Clinical Center Nis

Niš, Serbia

National University Hospital

Singapore, Singapore

National Cancer Centre

Singapore, Singapore

National Cancer Center

Gyeonggi-do, South Korea

Chonnam National University Hwasun Hospital

Jeollanam-do, South Korea

Seoul National University Hospital

Seoul, South Korea

Asan Medical Center

Seoul, South Korea

Yonsei University Health System/Severance Hospital

Seoul, South Korea

Insititut Catala D'Oncologia

L'Hospitalet de Llobregat, Barcelona, Spain

Complejo Hospitalario Universitario de Santiago (CHUS)

Santiago de Compostela, LA Coruna, Spain

Clinica Universitaria de Navarra

Pamplona, Navarre, Spain

Hospital General Univ. de Alicante

Alicante, Spain

Hospital Universitari Vall d'Hebron

Barcelona, Spain

Hospital Clínic i Provincial

Barcelona, Spain

ICO Badalona - Hospital Germans Trias i Pujol

Barcelona, Spain

Hospital General Universitario Gregorio Marañon

Madrid, Spain

Hospital Ramon y Cajal

Madrid, Spain

Hospital Universitario 12 de Octubre

Madrid, Spain

Centro Integral Oncologico Clara Campal

Madrid, Spain

Hospital Universitario Puerta de Hierro

Madrid, Spain

Hospital Quiron de Madrid

Madrid, Spain

Hospital Regional Universitario Carlos Haya

Málaga, Spain

Hospital Universitario Virgen del Rocio

Seville, Spain

Hospital Clínico Universitario de Valencia

Valencia, Spain

Kaohsiung Chang Gung Memorial Hospital

Kaohsiung City, Taiwan

National Taiwan Uni Hospital

Taipei, Taiwan

Taipei Veterans General Hospital

Taipei, Taiwan

Chang Gung Medical Foundation - Linkou

Taoyuan District, Taiwan

Faculty of Med. Siriraj Hosp.

Bangkok, Thailand

Prince of Songkla University

Hat Yai, Thailand

Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology

Adana, Turkey (Türkiye)

Akdeniz University Medical Faculty; Medical Oncology Department

Antalya, Turkey (Türkiye)

Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department

Edirne, Turkey (Türkiye)

Medipol University Medical Faculty; Oncology Department

Istanbul, Turkey (Türkiye)

Marmara University Pendik Training and Research Hospital; Medikal Onkoloji

Istanbul, Turkey (Türkiye)

Medikal Park Izmir Hospital

Kar??yaka, Turkey (Türkiye)

Hacettepe Uni Medical Faculty Hospital; Oncology Dept

Sihhiye/Ankara, Turkey (Türkiye)